Notfälle
Blutspende
Karriere
Presse
Forschung
Lehre
Patienten
Zuweiser

Selected Publications

Peer reviewed journal articles and reviews

  

Olzscha, H., Fedorov, O., Kessler, B.M., Knapp, S., and La Thangue, N.B. (2017). CBP/p300 Bromodomains Regulate Amyloid-like Protein Aggregation upon Aberrant Lysine Acetylation. Cell Chem Biol 24, 9-23.

 

New, M., Sheikh, S., Bekheet, M., Olzscha, H., Thezenas, M.L., Care, M.A., Fotheringham, S., Tooze, R.M., Kessler, B., and La Thangue, N.B. (2016). TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism. Cancer Res 76, 6975-6987.

 

Picaud, S., Fedorov, O., Thanasopoulou, A., Leonards, K., Jones, K., Meier, J., Olzscha, H., Monteiro, O., Martin, S., Philpott, M., et al. (2015). Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. Cancer Res 75, 5106-5119.

 

Olzscha, H., Sheikh, S., and La Thangue, N.B. (2015). Deacetylation of chromatin and gene expression regulation: a new target for epigenetic therapy. Crit Rev Oncog 20, 1-17.

 

Sheikh, S., Olzscha, H., and La Thangue, N.B. (2014). Oncology biomarkers in clinical practice – a new horizon. European Drug Target Review 1, 41-44.

 

Olzscha, H., New, M., and La Thangue, N.B. (2013). Clinical Exemplification of HDAC Inhibitors: From Bench to Clinic, and Back Again. The Journal of OncoPathology 1, 75-84.

 

New, M., Olzscha, H., Liu, G., Khan, O., Stimson, L., McGouran, J., Kerr, D., Coutts, A., Kessler, B., Middleton, M., et al. (2013). A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors. Cell Death Differ 20, 1306-1316.

 

New, M., Olzscha, H., and La Thangue, N.B. (2012). HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol 6, 637-656.

 

Olzscha, H., Schermann, S.M., Woerner, A.C., Pinkert, S., Hecht, M.H., Tartaglia, G.G., Vendruscolo, M., Hayer-Hartl, M., Hartl, F.U., and Vabulas, R.M. (2011). Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144, 67-78.

 

 

Book chapters

 

Olzscha, H., Bekheet, M.E., Sheikh, S., and La Thangue, N.B. (2016). HDAC Inhibitors. Methods in molecular biology 1436, 281-303.

 

Sheikh, S., Bekheet, M., Olzscha, H., and La Thangue, N.B. (2015). Predicting and Monitoring Responses to Epigenetic Drugs. In Drug Discovery in Cancer Epigenetics, G. Egger, and P. Arimondo, eds. (Waltham: Elsevier), 373-406.

 

 

Encyclopaedia articles

 

Olzscha, H., New, M., and La Thangue, N.B. (2013). Personalised Cancer Medicine: Fulfilling the Promise. In Encyclopaedia of Life Sciences, J.W. Sons, ed. (Chichester: John Wiley & Sons), 1-10.

 

 

Thesis

 

Olzscha, H. (2010). Analyse struktureller Determinanten der toxischen Wirkung amyloider Proteine. In Fakultät für Chemie und Pharmazie (Munich: Ludwig-Maximilians-Universität), 1-269.

 

 

Direktor:
Prof. Dr. Guido Posern

AG Proteinopathies: 
Dr. Heidi Olzscha
Tel.: +49 (0)345 557 3847
Fax: +49 (0)345 557-3811
Email Heidi Olzscha

Hausanschrift:
Institut für Physiologische Chemie
Hollystrasse 1
06114 Halle (Saale)

Assistenz der Institutsleitung:
Ines Knipping
Telefon: (0345) 557-3812 
Fax:        (0345) 557-3811
Email:    Email